Correlation of GLUT-1 Overexpression, Tumor Size, and Depth of Invasion with 18F-2-fluoro-2-deoxy-D-glucose Uptake by Positron Emission Tomography in Colorectal Cancer

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2006 Nov 3

PMID 17080242

Citations 34

Authors

Jinyu Gu

Hirofumi Yamamoto

Hiroki Fukunaga

Katsuki Danno

Ichiro Takemasa

Masataka Ikeda

Mitsuaki Tatsumi

Mitsugu Sekimoto

Jun Hatazawa

Tsunehiko Nishimura

Morito Monden

Affiliations

Soon will be listed here.

Abstract

We investigated the wide variability of 18F-2-fluoro-2-deoxy-D: -glucose (FDG) uptake, semiquantified as standardized uptake value (SUV), in positron emission tomography (PET) scanning, in 20 patients with colorectal cancer (CRC), including 1 with synchronous hepatic metastasis. The sensitivity of PET in CRC diagnosis was 100%, with a mean SUV of 8.0 (3.1-11.9). Tumor size and depth of invasion were associated with higher SUVs (P=.0004, .042, respectively). Strong glucose transporter-1 (GLUT-1) expression had significantly positive correlation with the SUV (r=.619, P=.003). GLUT-1 expression revealed positive staining in 17 (85%) of the 20 primary lesions. The central part of the tumor, thought to be relatively hypoxic, had stronger GLUT-1 expression and a higher SUV than the periphery, in both the primary tumor and hepatic metastatic foci. Our data suggest that the SUVs of FDG uptake in PET may be a noninvasive biomarker for advanced CRC, indicative of a large hypoxic tumor with deep invasion.

Citing Articles

F-18 FDG PET/CT Imaging in Normal Variants, Pitfalls and Artifacts in the Abdomen and Pelvis.

Vangu M, Momodu J Front Nucl Med. 2024; 1:826109.

PMID: 39355643 PMC: 11440875. DOI: 10.3389/fnume.2021.826109.

Value of glucose transport protein 1 expression in detecting lymph node metastasis in patients with colorectal cancer.

Kim H, Choi S, Heo T, Kim K, Lee J, Yoo M World J Clin Cases. 2024; 12(5):931-941.

PMID: 38414613 PMC: 10895641. DOI: 10.12998/wjcc.v12.i5.931.

Epigenetic and metabolic reprogramming in inflammatory bowel diseases: diagnostic and prognostic biomarkers in colorectal cancer.

Zayeri Z, Parsi A, Shahrabi S, Kargar M, Davari N, Saki N Cancer Cell Int. 2023; 23(1):264.

PMID: 37936149 PMC: 10631091. DOI: 10.1186/s12935-023-03117-z.

as diagnostic markers and therapeutic targets in LUAD patients through bioinformatic analysis.

Zhang Y, Qin H, Bian J, Ma Z, Yi H Front Pharmacol. 2022; 13:1045179.

PMID: 36518662 PMC: 9742449. DOI: 10.3389/fphar.2022.1045179.

F-FDG PET/CT metabolic parameters correlate with EIF2S2 expression status in colorectal cancer.

Yang J, Yuan L, Gao Y, Liu X, Wang Y, Zhou L J Cancer. 2021; 12(19):5838-5847.

PMID: 34475997 PMC: 8408126. DOI: 10.7150/jca.57926.

References

Paul A, Tatsumi M, Higuchi I, Fukunaga H, Yasuda T, Nishimura T . Gamma camera coincidence imaging with [18F]fluorodeoxyglucose in the pretreatment evaluation of patients with oesophageal cancer. Nucl Med Commun. 2003; 24(9):963-70. DOI: 10.1097/00006231-200309000-00004. View

Kubota K, Akasu T, Fujita S, Sugihara K, Moriya Y, Yamamoto S . Clinical and pathological prognostic indicators with colorectal mucinous carcinomas. Hepatogastroenterology. 2004; 51(55):142-6. View

Koga H, Matsuo Y, Sasaki M, Nakagawa M, Kaneko K, Hayashi K . Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma. Ann Nucl Med. 2003; 17(4):327-31. DOI: 10.1007/BF02988530. View

Fukunaga H, Sekimoto M, Ikeda M, Higuchi I, Yasui M, Seshimo I . Fusion image of positron emission tomography and computed tomography for the diagnosis of local recurrence of rectal cancer. Ann Surg Oncol. 2005; 12(7):561-9. DOI: 10.1245/ASO.2005.08.001. View

Kato H, Takita J, Miyazaki T, Nakajima M, Fukai Y, Masuda N . Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res. 2003; 23(4):3263-72. View

Yen T, See L, Lai C, Yah-Huei C, Ng K, Ma S . 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med. 2004; 45(1):22-9. View

Berger K, Nicholson S, Dehdashti F, Siegel B . FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol. 2000; 174(4):1005-8. DOI: 10.2214/ajr.174.4.1741005. View

Whiteford M, Whiteford H, Yee L, Ogunbiyi O, Dehdashti F, Siegel B . Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum. 2000; 43(6):759-67; discussion 767-70. DOI: 10.1007/BF02238010. View

Abdel-Nabi H, Doerr R, Lamonica D, Cronin V, Galantowicz P, Carbone G . Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology. 1998; 206(3):755-60. DOI: 10.1148/radiology.206.3.9494497. View

10.

Tian M, Zhang H, Nakasone Y, Mogi K, Endo K . Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging. 2003; 31(1):5-12. DOI: 10.1007/s00259-003-1316-9. View

11.

Hayashi N, Yamamoto H, Hiraoka N, Dono K, Ito Y, Okami J . Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology. 2001; 34(4 Pt 1):638-50. DOI: 10.1053/jhep.2001.28198. View

12.

Topal B, Flamen P, Aerts R, DHoore A, Filez L, Van Cutsem E . Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases. Eur J Surg Oncol. 2001; 27(2):175-9. DOI: 10.1053/ejso.2000.1075. View

13.

Furudoi A, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G . Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology. 2001; 60(2):162-9. DOI: 10.1159/000055314. View

14.

Chung J, Lee Y, Kim S, Jeong J, Lee D, Lee M . Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun. 2004; 25(1):11-7. DOI: 10.1097/00006231-200401000-00003. View

15.

Pugachev A, Ruan S, Carlin S, Larson S, Campa J, Ling C . Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys. 2005; 62(2):545-53. DOI: 10.1016/j.ijrobp.2005.02.009. View

16.

Rohren E, Turkington T, Coleman R . Clinical applications of PET in oncology. Radiology. 2004; 231(2):305-32. DOI: 10.1148/radiol.2312021185. View

17.

Wong C, Salem R, Qing F, Wong K, Barker D, Gates V . Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med. 2004; 45(11):1892-7. View

18.

Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H . Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer. 2002; 94(4):921-8. View

19.

Rajendran J, Mankoff D, OSullivan F, Peterson L, Schwartz D, Conrad E . Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004; 10(7):2245-52. DOI: 10.1158/1078-0432.ccr-0688-3. View

20.

Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G . Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 2003; 63(5):1138-43. View